4-[3-(4-fluorophenyl)-2-methyl-7-oxo-1H-pyrazolo[1-5-a]pyrimidin-5-yl]-1-piperidinecarboxylic-acid-ethyl-ester and Central-Nervous-System-Diseases

Transient receptor potential canonical (TRPC) channels are highly homologous, nonselective cation channels that form many homo- and heterotetrameric channels. These channels are highly abundant in the brain and kidney and have been implicated in numerous diseases, such as depression, addiction, and chronic kidney disease, among others. Historically, there have been very few selective modulators of the TRPC family in order to fully understand their role in disease despite their physiological significance. However, that has changed recently and there has been a significant increase in interest in this family of channels which has led to the emergence of selective tool compounds, and even preclinical drug candidates, over the past few years. This review will cover these new advancements in the discovery of TRPC modulators and the emergence of newly reported structural information which will undoubtedly lead to even greater advancements.

Topics: Animals; Central Nervous System Diseases; Humans; Neuroprotective Agents; TRPC Cation Channels